乳腺浸润性导管癌TOP2A基因状态与HER2及临床病理特征的关系

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (1298 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To detect the topoisomerase Ⅱ alpha(TOP2A) gene in breast invasive ductal carcinoma and explore its association with the status and expression of human epidermal growth factor receptor 2(HER2) gene, as well as the clinicopathological characteristics. Methods: The status of TOP2A gene was detected by fluorescence in situ hybridization(FISH), the amplification of HER2 gene was detected by dualcolor silverenhanced insitu hybridization(DISH) and the expression of HER2 gene by immunohistochemistry among 371 patients with breast invasive ductal carcinoma. Results: In 371 patients with breast invasive ductal carcinoma, 64 cases(17.25%) of TOP2A amplification, 12 cases(3.24%) of TOP2A deletion and 122 cases(32.88%) of HER2 amplification were found, with the abnormality rate 20.49%(76/371) of TOP2A. In TOP2A amplification, 53 cases of HER2 amplification and 11 cases of nonamplification were found.In TOP2A deletion, 9 cases of HER2 amplification and 3 cases of nonamplification were found. In TOP2A without amplification or deletion, 60 cases of HER2 amplification and 235 cases of nonamplification were found. The expression of HER2 was 0～1+, 2+, 3+ and the corresponding amplification rate of TOP2A gene was 4.69%, 23.44%, 71.88%, respectively. The deletion rate of TOP2A was 66.67%(8/12) at HER2 expression 3+. The status of TOP2A had no statistical association with age, gender, cancer site and lymphatic metastasis(P>0.05), while it was statistically correlated with histological classification and tumor diameter(P<0.05). Conclusion: TOP2A gene was correlated with the abnormality of HER2 gene, and the amplification of TOP2A increased with the increasing expression of HER2 gene. The abnormal rate of TOP2A in invasive breast cancer was relatively high among the patients with tumor diameter of2～5 cm and higher histological classification.

Received: 13 October 2017

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2018/V28/I01/70

［1］Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013\[J\]. CA Cancer J Clin, 2013, 63(1): 11-30.
［2］Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer\[J\]. Cancer Epidemiol Biomarkers Prev, 2005, 14(1): 20-26.
［3］Deb S, Jene N, Kconfab Investigators, et al. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCAassociated carcinomas\[J\]. BMC Cancer, 2012, 12: 510.
［4］O′Malley FP, Chia S, Tu D, et al. Topoisomerase Ⅱ alpha and responsiveness of breast cancer to adjuvant chemotherapy\[J\]. J Natl Cancer Inst, 2009, 101(9): 644-650.
［5］Tubbs R, Barlow WE, Budd GT, et al. Outcome of patients with earlystage breast cancer treated with doxorubicinbased adjuvant chemotherapy as a function of HER2 and TOP2A status\[J\]. J Clin Oncol, 2009, 27(24): 3881-3886.
［6］Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysisdirected individualized therapy in advanced nonsmallcell lung cancer\[J\]. J Clin Oncol, 2007, 25(19): 2741-2746.
［7］Slamon DJ, Press MF. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers\[J\]. J Natl Cancer Inst, 2009, 101(9): 615-618.
［8］华骁帆. 早期非特殊性浸润性乳腺癌TOP2a蛋白表达与分级、分期及分子分型相关性分析\[D\]. 苏州：苏州大学，2016.
［9］Siddiqa A, Long LM, Li L, et al. Expression of HER2 in MCF7 breast cancer cells modulates antiapoptotic proteins Survivin and Bcl2 via the extracellular signalrelated kinase (ERK) and phosphoinositide3 kinase (PI3K) signalling pathways\[J\]. BMC Cancer, 2008, 8: 129.
［10］许洁, 陈洁, 张科平, 等. 非特殊性浸润性乳腺癌TOP2A基因状态与分级、HER2和Ki67的相关性\[J\]. 临床与实验病理学杂志, 2015, 31(5) : 576-578.
［11］蒋奕，叶洪涛，姬逸男，等.乳腺组织TOP2A和HER2/neu扩增与临床病理因素相关性研究［J］.中华肿瘤防治杂志，2017，24（1）：30-33.
［12］Wolff AC, Hammon ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing in breast cancer\[J\]. Arch Pathol Lab Med, 2007, 131(1): 18-43.
［13］Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update\[J\]. J Clin Oncol, 2013, 31(31): 3997-4013.
［14］Brase JC, Schmidt M, Fischbach T, et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction\[J\]. Clin Cancer Res, 2010, 16(8): 2391-2401.
［15］Romero A, Caldés T, DíazRubio E, et al. Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?\[J\]. Clin Transl Oncol, 2012, 14(3): 163-168.
［16］Badawy OM, Loay I. FISH analysis of TOP2A and HER2 aberrations in female breast carcinoma on archived material: egyptian NCI experience\[J\]. Appl Immunohistochem Mol Morphol, 2017.\[Epub ahead of print\]
［17］刘春萍, 逯翀, 田源,等. 乳腺癌Her2与TOP2A基因表达对新辅助化疗效果的预测价值\[J\]. 中国普通外科杂志, 2010, 19(11): 1200-1203.
［18］明洁, 逯翀, 田元,等. 乳腺癌HER2与TOP2A的表达及其相关性\[J\]. 解剖学报, 2010, 41(3): 391-394.
［19］张成娟, 董凤梅, 徐本玲,等. Ki67、Her2及Top2A在乳腺癌中的扩增表达与蒽环类药物疗效关系的研究\[J\]. 肿瘤基础与临床, 2017, 30(1): 11-14.
［20］汤小江, 周瑜辉, 张伟, 等. TOP2A基因表达与乳腺癌HER2通路的相关性\[J\]. 西安交通大学学报（医学版）, 2015, 36(4): 519-522, 557.
［21］Barinoff J, Traut A, Bauerschlag D, et al. Chemotherapy for 70yearold women with breast cancer in Germany: a survey by the German breast group\[J\]. Geburtshilfe Frauenheilkd, 2013, 73(5): 433-439.
［22］Gogia A, Raina V, Deo SV, et al. Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience\[J\]. Asian Pac J Cancer Prev, 2014, 15(5): 1989-1992.